Accumulating evidence supports the incorporation of tumor mutational burden, microsatellite instability, neoantigen load, and gene expression signatures as adjunctive or composite biomarkers that may refine patient stratification beyond PD-L1 status. Here, CD274 is linked to neoplasm.